Core Insights - Bright Minds Biosciences, Inc. is focused on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other CNS disorders [1][3][4] - The company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025, and at the Jefferies Global Healthcare Conference in London [1] - The company has granted stock options to directors, officers, and consultants to purchase a total of 43,000 common shares at an exercise price of US$54.47 per share for five years [2] Company Overview - Bright Minds Biosciences is a biotechnology company developing innovative treatments for neurological and psychiatric disorders, with a pipeline targeting conditions with high unmet medical needs [3] - The company has developed a unique platform of highly selective serotonergic agonists, providing a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry [4]